In short
Clinical trials investigating AB521 are studying treatment in people with advanced or metastatic clear cell renal cell carcinoma. The main goal is to compare disease control and safety-related outcomes in a Phase 3 trial. These studies focus on patients with this type of kidney cancer who are eligible for randomization.
Key points
- AB521 is being studied in a Phase 3 randomized trial for people with advanced or metastatic clear cell renal cell carcinoma, a type of kidney cancer. The study compares one treatment group against a control group. The main goal is to measure progression-free survival, which shows how long the cancer stays from getting worse. The trial is authorised and plans to enroll 720 participants. The study uses blinded independent review and RECIST 1.1 to assess cancer progression.
Trial overview
The available trial for AB521 is a randomized Phase 3 trial in patients with advanced clear cell renal cell carcinoma and metastatic clear cell renal cell carcinoma. The study is authorised and plans to enroll 720 people.
This trial is designed to compare two treatment approaches: casdatifan plus cabozantinib versus placebo plus cabozantinib. The brief summary states that the main purpose is to compare progression-free survival in all randomized patients.
Who is being studied
The trial focuses on people with advanced clear cell renal cell carcinoma or metastatic clear cell renal cell carcinoma. Clear cell renal cell carcinoma is a type of kidney cancer, and metastatic means the cancer has spread to other parts of the body.
The source data does not give a full list of all entry rules, but it shows that the study is meant for patients with these specific cancer types.
Treatment groups and randomization
The study is randomized, which means participants are assigned by chance to a study group. Randomization helps make the groups more balanced and makes the comparison more reliable.
One group receives casdatifan with cabozantinib, and the other group receives placebo with cabozantinib. A placebo is a look-alike treatment that does not contain the active study medicine.
The trial record lists oral cabozantinib and oral placebo in the intervention section, along with casdatifan.
Study phase and size
This is a Phase 3 study. Phase 3 trials are larger studies that compare treatments in many patients to see how well they work.
The planned enrollment is 720 participants. That means the trial aims to include 720 people in total if recruitment is completed as planned.
What the trial measures
The main endpoint is progression-free survival (PFS). PFS is the time from randomization until the cancer gets worse, called progressive disease, or until death from any cause, whichever happens first.
The study uses BICR, which means blinded independent central review, to assess progression according to RECIST 1.1. In simple terms, outside reviewers check scans without knowing which treatment the patient received, and RECIST 1.1 is a standard way to measure tumor change on scans.
The brief summary says the trial is comparing PFS between the casdatifan plus cabozantinib group and the placebo plus cabozantinib group in all randomized patients.